This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-EDB scFv to IL12. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the EDB as well as the biological activity of IL12. The fusion protein displays an excellent tumor targeting performance in vivo. Considering the fact that the tumor targeting ability of scFv (L19) in patients with cancer has been demonstrated using scintigraphic methods, and that scFv (L19)-based antibody-cytokine fusion are currently entering clinical trials. This immunocytokine was designed for treating Advanced solid tumors, Advanced pancreatic cancer, Metastatic melanoma.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For Research Use Only. Not For Clinical Use.